Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy

Theranostics

Volumn 5, Issue 4, 2015, Pages 378-398

  Ding, Li ^a   Tian, Caiping ^a   Feng, Song ^a   Fida, Guissi ^a   Zhang, Congying ^a   Ma, Yuxiang ^a   Ai, Guanhua ^a   Achilefu, Samuel ^b   Gu, Yueqing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EGFR1; HER2

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 1 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MACROGOL 20000; MULTIVALENT ANTIBODY COMPRISED OF NANOBODY AND AFFIBODY; NANOBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; HYBRID PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SYNTHESIS; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE AEG 1; ONCOGENE C FOS; ONCOGENE C JUN; ONCOGENE C MYC; PROTEIN EXPRESSION; RAT; STEADY STATE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; ESCHERICHIA COLI; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; METABOLISM; NEOPLASMS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SINGLE-DOMAIN ANTIBODIES; TREATMENT OUTCOME;

EID: 84924291069     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.10084     Document Type: Article

References (74)

1. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO. 2000; 19: 3159-67.
2. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005; 23: 2445-59.
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol. 2001; 2: 127-37.
4. Yoshida T, Okamoto I, Okabe T, et al. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer. 2008; 122 (7): 1530-8.
5. van de Water JAJM, Bagci-Onder T, Agarwal AS, et al. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proc Natl Acad Sci U S A. 2012; 109 (41): 16642-7.
6. García-Echeverría C. Protein and lipid kinase inhibitors as targeted anticancer agents of the RAS/RAF/MEK and PI3K/PKB pathways. Purinergic Signal. 2009; 5 (1): 117-25.
7. Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002; 62 (14): 4132-41.
8. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004; 4: 361-70.
9. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000; 19: 6550-65.
10. Slamon DJ, Godolphin W, Holt JA, el al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707-12.
11. Dent S, Oyan B, Honig A, et al. HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials. Cancer Treat Rev. 2013; 39: 622-31.
12. Chen JS, Lan K, Hung MC. Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist Updat. 2003; 6: 129-36.
13. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002; 2: 127-37.
14. Baselga J, Norton L, Albanell J, et al. Recombinant Humanized Anti-HER2 Antibody (HerceptinTM) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts. Cancer Res. 1998; 58: 2825-31.
15. Reid A, Vidal L, Shaw H, et al. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer. 2007; 43: 481-9.
16. Huang F, Greer A, Hurlburt W, et al. The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) Rationale for Combining with EGFR/HER2 Inhibitors. Cancer Res. 2009; 69: 161-70.
17. Larbouret C, Robert B, Navarro-Teulon I, et al. In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas. Clin Cancer Res. 2007; 13: 3356-62.
18. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2006; 355: 2733-43.
19. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006; 6: 714-27.
20. Liu Z, Niu G, Wang F, et al. 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging. 2009; 36: 1483-94.
21. Chames P, Van Regenmortel M, Weiss E, et al. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009; 157 (2): 220-33.
22. Dreier T, Lorenczewski G, Brandl C, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 2002; 100 (6): 690-7.
23. Offner S, Hofmeister R, Romaniuk A, et al. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol. 2006; 43: 763-71.
24. Holt LJ, Herring C, Jespers LS, et al. Domain antibodies: proteins for therapy. Trends Biotechnol. 2003; 21: 484-90.
25. Nelson AL. Antibody fragments Hope and hype. mAbs. 2010; 2 (1): 77-83.
26. Eklund M, Axelsson L, Uhlen M, et al. Anti-idiotypic protein domains selected from protein A-based affibody libraries. Proteins. 2002; 48 (3): 454-62.
27. Gao J, Chen K, Miao Z, et al. Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials. 2011; 32: 2141-8.
28. Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther. 2005; 5 (1): 111-24.
29. Oliveira S, Schiffelers RM, Veeken J, et al. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release. 2010; 145: 165-75.
30. Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol. 2007; (1): 13-22.
31. Roovers RC, Vosjan MJWD, Laeremans T, et al. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer. 2011; 129 (8): 2013-24.
32. Ekerljung L, Lindborg M, Gedda L, et al. Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line. Biochem Biophys Res Commun. 2008; 377 (2): 489-94.
33. Friedman M, Lindström S, Ekerljung L, et al. Engineering and characterization of a bispecific HER2× EGFR-binding affibody molecule. Biotechnol Appl Biochem. 2009; 54 (2): 121-31.
34. Gao J, Chen K, Miao Z, et al. Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials. 2011; 32: 2141-8.
35. Orlova A, Magnusson M, Eriksson TLJ, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006; 66: 4339-48.
36. Cortez-Retamozo V, Backmann N, Senter PD, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 2004; 64 (8): 2853-7.
37. Huang L, Gainkam LOT, Caveliers V, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol. 2008, 10 (3): 167-75.
38. Wikman M, Steffen AC, Gunneriusson E, et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel. 2004; 17 (5): 455-62.
39. Gainkam LOT, Huang L, Caveliers V, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008; 49 (5): 788-95.
40. Steffen AC, Wikman M, Tolmachev V, et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm. 2005; 20 (3): 239-48.
41. Ekerljung L, Lennartsson J, Gedda L. The HER2-Binding Affibody Molecule (ZHER2: 342) 2 Increases Radiosensitivity in SKBR-3 Cells. PloS One. 2012; 7 (11): e49579.
42. Cao J, Wan S, Tian J, et al. Fast clearing RGD-based near-infrared fluorescent probes for in vivo tumor diagnosis. Contrast Media Mol Imaging. 2012; 7: 390-402.
43. Albrecht H, DeNardo GL, DeNardo SJ. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility. J Immunol Methods. 2006; 310 (1): 100-16.
44. Bobrovnik SA, Komisarenko SV, Ilyina LV. Novel and simple ELISA-based method for antibody affinity determination. Ukr Biokhim Zh. 2004, 77 (2): 169-74.
45. Kingshott P, Thissen H, Griesser HJ. Effects of cloud-point grafting, chain length, and density of PEG layers on competitive adsorption of ocular proteins. Biomaterials. 2002; 23 (9): 2043-56.
46. Edwards III CK, Martin SW, Seely J, et al. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv Drug Deliv Rev. 2003; 55 (10): 1315-36.
47. Gaudriault G, Vincent JP. Selective labeling of a-or ?-amino groups in peptides by the Bolton-Hunter reagent. Peptides. 1992; 13 (6): 1187-92.
48. Gainkam LOT, Huang L, Caveliers V, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008; 49 (5): 788-95.
49. Bobrovnik SA. Determination of antibody affinity by ELISA. Theory. J Biochem Biophys Methods. 2003; 57 (3): 213-36.
50. Beatty JD, Beatty BG, Vlahos WG. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods. 1987; (1): 173-9.
51. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001; 37: 3-8.
52. Normanno N, Luca AD, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366: 2-16.
53. Hartman Z, Zhao H, Agazie YM. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling. Oncogene. 2013; 32: 4169-80.
54. Emdad L, Sarkar D, Su Z, et al. Activation of the Nuclear Factor ?B Pathway by Astrocyte Elevated Gene-1: Implications for Tumor Progression and Metastasis. Cancer Res. 2006; 66: 1509-16.
55. Hu G, Wei Y, Kang Y. The Multifaceted Role of MTDH/AEG-1 in Cancer Progression. Clin Cancer Res. 2009; 15: 5615-20.
56. Lee S, Su Z, Emdad L, et al. Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Prog Nucleic Acid Res Mol Biol. 2006; 103: 17390-5.
57. Denis N, Kitzis A, Kruh J, et al. Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by c-myc. Oncogene. 1991; 6: 1453-7.
58. Sheng H, Shao J, Dubios RN. Akt/PKB Activity Is Required for Ha-Ras-mediated Transformation of Intestinal Epithelial Cells. J Biol Chem. 2001; 276: 11498-504.
59. Rajagopalan S, Politi PM, Sinha BK, et al. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. 1988; 48 (17): 4766-9.
60. Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol. 2009; 13: 245-55.
61. Kono K, Takahashi A, Ichihara F, et al. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res. 2002; 62 (20): 5813-7.
62. Press MF, Lenz HJ. EGFR, HER2 and VEGF Pathways. Drugs. 2007; 67: 2045-75.
63. Hommelgaard AM, Lerdrup M, Deurs B. Association with membrane protrusions makes erbB2 an internalization-resistant receptor. Mol Biol Cell. 2004; 15: 1557-67.
64. Earp HS, Dawson TL, Li X, et al. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat. 1995; 35: 115-32.
65. Tauchi K, Hori S, Itoh H, et al. Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. Virchows Arch. 1989; 416: 65-73.
66. Dam PA, Vergote IB, Lowe DG, et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol. 1994; 47: 914-9.
67. Luca AD, Maiello MR, D'Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012; 16: S17-S27.
68. Yu C, Chen K, Zheng H, et al. Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis. Carcinogenesis. 2009; 30: 894-901.
69. Cortez-Retamozo V, Lauwereys M, Gobert M, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer. 2002; 98 (3): 456-62.
70. Nilsson J, Larsson M, Stahl S, et al. Multiple affinity domains for the detection, purification and immobilization of recombinant proteins. J Mol Recognit. 1996; (5-6): 585-94.
71. Nilsson J, Ståhl S, Lundeberg J, et al. Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins. Protein Expr Purif. 1997, 11 (1): 1-16.
72. He XH, Shaw PC, Tam SC. Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. Life Sci. 1999; 65 (4): 355-68.
73. Ledón N, Casacó A, Casanova E, et al. Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models. Placenta. 2011; 32 (7): 531-4.
74. Dokter W, Ubink R, van der Lee M, et al. Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform. Mol Cancer Ther; 2014, 13 (11): 2618-29.